Peer-influenced content. Sources you trust. No registration required. This is HCN.
Journal of Pharmaceutical Policy and Practice
Unraveling Patient Perspectives on DOAC Safety: Key Findings and Implications for Healthcare Practice A recent study that delves into the complex interactions of direct oral anticoagulants (DOACs) usage offers insightful information about patient experiences and suggests ways to increase patients’ safety and adherence.
Cardiology June 6th 2023
SingleCare
Navigating the Interplay of Eliquis and Dietary Habits As physicians, understanding the nuances of apixaban (Eliquis) and its interaction with diet is crucial for optimal patient care. While taking Eliquis, there are no specific foods to avoid, but people with cardiovascular issues should steer clear of coffee and foods heavy in fat.
The New England Journal of Medicine
Evaluating the Timing of DOAC Initiation Post-Stroke: Key Findings Here are the key findings from a recent multi-country, open-label research that explores the best time to start direct oral anticoagulants (DOACs) in atrial fibrillation patients after a stroke.
Epilepsy Currents
Dive into the intriguing findings from the PEACH trial on prophylactic levetiracetam for seizure prevention in intracerebral haemorrhage patients. The PEACH trial aimed to test prophylactic levetiracetam for seizure prevention in acute intracerebral haemorrhage (ICH) patients. Early seizures within seven days of stroke onset occur in almost 30% of patients. However, current guidelines lack strategies to manage this issue. Despite being prematurely stopped, the trial showed promise. In this double-blind, randomised, placebo-controlled trial, 50 patients received either levetiracetam or a placebo. Clinical or electrographic seizures were seen in 16% of levetiracetam patients and 43% of placebo patients within 72 hours. Interestingly, these seizures were only electrographic. Adverse events included headaches and pain, but no treatment-related deaths were reported. The findings suggest levetiracetam may prevent acute seizures in ICH patients, but larger studies are needed. Acute seizures can lead to increased morbidity and mortality. The trial found fewer seizures within 72 hours of study inclusion in the levetiracetam group. This is promising, but more research is required. This study opens avenues for further investigation. It raises questions about early detection of interictal epileptiform activity and the need for prophylactic levetiracetam. It also underscores the need to understand which factors influence seizure […]
Internal Medicine May 23rd 2023
Cleveland Clinic Journal of Medicine
This 1-Minute Consult reviews the bedside workup of delirium and possible stroke and reviews the cases for – and against – imaging.
Geriatrics May 2nd 2023
MDLinx
An Idaho man received $13.5 million after a nearby hospital missed his stroke diagnosis by more than 12 hours. The jury’s finding that the emergency physician engaged in “reckless misconduct” allowed this case to exceed the usual Idaho cap on judgments for cases of this nature of $400,000.00.
All Specialties April 18th 2023